Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036
- PMID: 28576506
- DOI: 10.1016/j.eururo.2017.05.031
Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036
Comment in
-
Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.Eur Urol. 2017 Dec;72(6):e158-e159. doi: 10.1016/j.eururo.2017.05.030. Epub 2017 May 31. Eur Urol. 2017. PMID: 28576503 No abstract available.
Comment on
-
Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.Eur Urol. 2018 Feb;73(2):168-175. doi: 10.1016/j.eururo.2017.03.036. Epub 2017 Apr 8. Eur Urol. 2018. PMID: 28400167 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical